Contraceptives Market By Type (Male Contraceptives, Female Contraceptives), By Product Type (Contraceptive Drugs [Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives {Patches, Gels, Others}], Contraceptive Devices [Condoms, Diaphragms, Cervical Caps, Vaginal Rings, Intrauterine Devices (IUDs), Subdermal Contraceptive Implants]), by geography is expected to grow at a steady CAGR forecast till 2027 owing to increasing awareness about sexually transmitted diseases, rise in government initiatives for population control.

Global Contraceptives Market was valued at USD 24.17 billion in 2021, growing at a CAGR of 5.19% during the forecast period from 2022 to 2027 to reach USD 32.61 billion by 2027. The Contraceptives market is witnessing positive growth owing to the increasing awareness about sexually transmitted diseases, rise in government initiatives for population control, upsurge in unintended pregnancies, technological innovations leading to effective contraception, thereby contributing to the growth of the Contraceptives market during the forecast period...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H2 2017, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics unde...

Summary

GlobalData's clinical trial report, “Male Contraception Global Clinical Trials Review, H2, 2017" provides an overview of Male Contraception clinical trials scenario. This report provides top line data relating to the clinical trials on Male Contraception. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain co...

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Female Contraception Overview 9
Therapeutics Development 10
Pipeline Products for Female Contraception - Overview 10
Pipeline Products for Female Contraception - Comparative Analysis 11
Female Contraception - Therapeutics under Development by Companies 12
Female Contraception - Therapeutics under Investigation by Universities/Institutes 13
Female Contraception - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Female Contraception - Products under Development by Companies 17
Female Contraception - Products under Investigation by Universities/Institutes 19
Female Contraception - Companies Involved in Therapeutics Development 20
Addex Therapeutics Ltd 20
Agile Therapeutics Inc 21
ANI Pharmaceuticals Inc 22
Bayer AG 23
Evofem Inc 24
Hervana Ltd 25
Mithra Pharmaceuticals SA 26
Orbis Biosciences Inc 27
Teva Pharmaceutical...